文献速递糖尿病

成人1型糖尿病中高级混合闭环疗法与常规治疗对比(ADAPT):一项随机对照研究

Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study.
PubMed 文献 · Lancet Diabetes Endocrinol · 2022-09-01

ADAPT试验为前瞻性、多中心、开放标签随机对照研究,纳入使用每日多次胰岛素注射联合间歇扫描式持续葡萄糖监测且HbA1c≥8%的成人1型糖尿病患者。6个月时AHCL组HbA1c较基线下降1.54%,对照组下降0.20%,模型估计组间差异为-1.42%(95%CI -1.74至-1.10;p<0.0001)。

要点

  • 6个月时AHCL组HbA1c从9.00%降至7.32%,降幅1.54%,对照组从9.07%降至8.91%,降幅0.20%。
  • 模型估计的组间HbA1c变化差异为-1.42%(95%CI -1.74至-1.10;p<0.0001),支持AHCL治疗。
  • 两组均未发生糖尿病酮症酸中毒、严重低血糖或与研究装置相关的严重不良事件。

核心结论

  • 在使用每日多次胰岛素注射联合间歇扫描式持续葡萄糖监测且HbA1c至少8%的1型糖尿病患者中,使用AHCL可带来超越每日多次胰岛素注射联合间歇扫描式持续葡萄糖监测的血糖控制获益。
  • 这些数据支持在血糖未达标的1型糖尿病患者中更广泛地使用AHCL。

研究设计与样本

  • ADAPT试验为前瞻性、多中心、开放标签、随机对照试验,涉及3个欧洲国家(法国、德国和英国)的14个中心。
  • 纳入年龄至少18岁、1型糖尿病病程至少2年、HbA1c至少8%(64 mmol/mol)且使用每日多次胰岛素注射联合间歇扫描式持续葡萄糖监测(队列A)或实时持续葡萄糖监测(队列B)至少3个月的患者;本文仅报告队列A的结果。
  • 参与者按1:1随机分配至AHCL治疗组或继续每日多次胰岛素注射联合持续葡萄糖监测组,干预6个月,采用研究者设盲的区组随机化程序。
  • 主要终点为在意向治疗人群中,AHCL治疗组与每日多次胰岛素注射联合间歇扫描式持续葡萄糖监测组之间从基线至6个月平均HbA1c变化值的组间差异,采用以研究分组和时期为因子的重复测量随机效应模型分析。
  • 研究在ClinicalTrials.gov注册,注册号为NCT04235504。

主要发现

  • 2020年7月13日至2021年3月12日期间,筛查105人,82人被随机分配接受治疗(每组41人)。
  • 6个月时,AHCL组平均HbA1c下降1.54%(SD 0.73),从9.00%降至7.32%;每日多次胰岛素注射联合间歇扫描式持续葡萄糖监测组下降0.20%(SD 0.80),从9.07%降至8.91%;模型估计的组间差异为-1.42%(95%CI -1.74至-1.10;p<0.0001)。
  • 两组均未发生糖尿病酮症酸中毒、严重低血糖或与研究装置相关的严重不良事件;导入期发生两例严重低血糖事件。
  • AHCL组发生15例装置相关非严重不良事件,每日多次胰岛素注射联合间歇扫描式持续葡萄糖监测组发生3例。
  • 共发生两例严重不良事件(每组各一例):AHCL组一例为乳腺癌,每日多次胰岛素注射联合间歇扫描式持续葡萄糖监测组一例为玻璃体出血。

关键数值与推荐

  • AHCL组6个月时HbA1c较基线变化为-1.54%(SD 0.73),从9.00%降至7.32%。
  • 每日多次胰岛素注射联合间歇扫描式持续葡萄糖监测组6个月时HbA1c较基线变化为-0.20%(SD 0.80),从9.07%降至8.91%。
  • 模型估计的组间HbA1c变化差异为-1.42%(95%CI -1.74至-1.10;p<0.0001)。

临床怎么用

  • 作者认为,对于使用每日多次胰岛素注射联合间歇扫描式持续葡萄糖监测且HbA1c至少8%的1型糖尿病患者,使用AHCL可带来超越每日多次胰岛素注射联合间歇扫描式持续葡萄糖监测的血糖控制获益。
  • 作者认为,这些数据支持在血糖未达标的1型糖尿病患者中更广泛地使用AHCL。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adults with type 1 diabetes who are treated with multiple daily injections of insulin plus intermittently scanned continuous glucose monitoring (isCGM) can have suboptimal glucose control. We aimed to assess the efficacy of an advanced hybrid closed loop (AHCL) system compared with such therapy in this population. METHODS: The Advanced Hybrid Closed Loop Study in Adult Population with Type 1 Diabetes (ADAPT) trial is a prospective, multicentre, open-label, randomised controlled trial that involved 14 centres in three European countries (France, Germany, and the UK). We enrolled patients who were at least 18 years of age, had a type 1 diabetes duration of at least 2 years, HbA1c of at least 8% (64 mmol/mol), and were using multiple daily injections of insulin plus isCGM (cohort A) or real time continuous glucose monitoring (cohort B) for at least 3 months. Here, only results for cohort A are reported. Participants were randomly allocated 1:1 to AHCL therapy or continuation of multiple daily injections of insulin plus continuous glucose monitoring for 6 months with an investigator-blinded block randomisation procedure. Participants and treating clinicians could not be masked to the arm assignment. The primary endpoint was the between-group difference in mean HbA1c change from baseline to 6 months in the intention-to-treat population using AHCL therapy and those using multiple daily injections of insulin plus isCGM. The primary endpoint was analysed using a repeated measures random-effects model with the study arm and period as factors. Safety endpoints included the number of device deficiencies, severe hypoglycaemic events, diabetic ketoacidosis, and serious adverse events. This study is registered with ClinicalTrials.gov, NCT04235504. FINDINGS: Between July 13, 2020, and March 12, 2021, 105 people were screened and 82 randomly assigned to treatment (41 in each arm). At 6 months, mean HbA1c had decreased by 1·54% (SD 0·73), from 9·00% to 7·32% in the AHCL group and 0·20% (0·80) in the multiple daily injections of insulin plus isCGM from 9·07% to 8·91% (model-based difference -1·42%, 95% CI -1·74 to -1·10; p<0·0001). No diabetic ketoacidosis, severe hypoglycaemia, or serious adverse events related to study devices occurred in either group; two severe hypoglycaemic events occurred in the run-in phase. 15 device-related non-serious adverse events occurred in the AHCL group, compared with three in the multiple daily injections of insulin plus isCGM group. Two serious adverse events occurred (one in each group), these were breast cancer (in one patient in the AHCL group) and intravitreous haemorrhage (in one patient in the multiple daily injections of insulin plus isCGM group). INTERPRETATION: In people with type 1 diabetes using multiple daily injections of insulin plus isCGM and with HbA1c of at least 8%, the use of AHCL confers benefits in terms of glycaemic control beyond those that can be achieved with multiple daily injections of insulin plus isCGM. These data support wider access to AHCL in people with type 1 diabetes not at target glucose levels. FUNDING: Medtronic International Trading Sàrl.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Choudhary P, Kolassa R, Keuthage W, et al. Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study. Lancet Diabetes Endocrinol. 2022. PMID: 36058207. doi:10.1016/S2213-8587(22)00212-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。